Continuous Subcutaneous Apomorphine Infusion (CSAI) Improved Confidence When Engaging in Everyday Activities: Survey of InfusON Study Participants
Objective: Evaluate participants' perceptions of their confidence when engaging in daily activities and interpersonal relationships while using CSAI therapy, relative to the period before CSAI…Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants
Objective: Obtain patient feedback on experiences initiating and using continuous subcutaneous apomorphine infusion (CSAI). Background: Previously reported data from the ongoing InfusON study demonstrated that…Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-Term Data from the Ongoing InfusON Extension Study
Objective: Evaluate outcomes (up to 3 years) from the ongoing Extension Period of the InfusON study (NCT02339064) of continuous subcutaneous apomorphine infusion (CSAI). Background: Primary…Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations
Objective: Review available efficacy data from Phase 3 studies assessing continuous subcutaneous apomorphine infusion (CSAI) for patients with PD experiencing motor fluctuations. Background: Despite decades…Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment
Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…Baseline Variables Associated with Apomorphine Sublingual Film Retention
Objective: The aim of this analysis was to identify the baseline variables that differ between patients who completed Study CTH-301 and those who discontinued during…Oropharyngeal Adverse Events in Parkinson’s Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film
Objective: This post-hoc analysis of Study CTH-301 assessed the occurrence of oropharyngeal treatment-emergent adverse events (TEAEs) in patients with Parkinson’s disease included in this study.…Safety and Efficacy of Sublingual Apomorphine in Parkinson’s Patients with or without Concomitant Dopamine Agonists Use
Objective: This post-hoc analysis of Study CTH-301 aimed to assess the safety and efficacy of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease with…The impact of long-term continuous subcutaneous apomorphine infusion on the reduction of remaining medications in levodopa equivalent dosage and on increasing plasma vitamin B12 levels in patients with advanced Parkinson’s disease
Objective: To evaluate the plasma levels of vitamin B and homocysteine among 28 advanced PD patients with motor complications before and after continued used of…VALIdation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson’s disease (VALIDATE)
Objective: To externally validate the Dutch Device-Aided Therapy Screening tool (D-DATS) and to compare it with the 5-2-1 criteria. Background: Timely identification of patients with…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 13
- Next Page »